{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:23:19Z","timestamp":1771503799080,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA046721"],"award-info":[{"award-number":["R01DA046721"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jsat.2022.108835","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:03:25Z","timestamp":1656727405000},"page":"108835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release"],"prefix":"10.1016","volume":"141","author":[{"given":"Ali","family":"Jalali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Polsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chien","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George E.","family":"Woody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jsat.2022.108835_bb0005","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/add.14946","article-title":"Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: A systematic review and meta-analysis","volume":"115","author":"Bahji","year":"2020","journal-title":"Addiction"},{"issue":"23","key":"10.1016\/j.jsat.2022.108835_bb0010","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: An application of the non-parametric bootstrap","volume":"19","author":"Barber","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2022.108835_bb0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009","volume":"159","author":"Binswanger","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108835_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2013A high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2022.108835_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/sim.7956","article-title":"Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data","volume":"38","author":"Brand","year":"2019","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2022.108835_bb0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/add.13803","article-title":"High risk of overdose death following release from prison: Variations in mortality during a 15- year observation period","volume":"112","author":"Bukten","year":"2017","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2022.108835_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","article-title":"Retention strategies for medications for opioid use disorder in adults: A rapid evidence review","volume":"15","author":"Chan","year":"2021","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2022.108835_bb0040","unstructured":"EuroQol, n.d.EuroQol (n.d.). Retrieved 20 February from https:\/\/euroqol.org."},{"key":"10.1016\/j.jsat.2022.108835_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as- usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10","key":"10.1016\/j.jsat.2022.108835_bb0050","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/add.13877","article-title":"Substance use disorders in prisoners: An updated systematic review and meta-regression analysis in recently incarcerated men and women","volume":"112","author":"Fazel","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108835_bb0055","series-title":"Drug Abuse Treatment Cost Analysis Program (DATCAP): User\u2019s manual","author":"French","year":"2003"},{"issue":"5","key":"10.1016\/j.jsat.2022.108835_bb0060","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0740-5472(97)00132-3","article-title":"A structured instrument for estimating the economic cost of drug abuse treatment. The drug abuse treatment cost analysis program (DATCAP)","volume":"14","author":"French","year":"1997","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108835_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jsat.2017.04.010","article-title":"Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison","volume":"85","author":"Friedmann","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2022.108835_bb0070","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/add.13073","article-title":"A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence","volume":"110","author":"Gisev","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108835_bb0075","series-title":"Economic evaluation in clinical trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.jsat.2022.108835_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108241","article-title":"A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail","volume":"128","author":"Gordon","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2022.108835_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"key":"10.1016\/j.jsat.2022.108835_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2020.02.002","article-title":"Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future","volume":"112S","author":"Jalali","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108835_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/epirev\/mxac006","article-title":"Econometric issues in prospective economic evaluations alongside clinical trials: Combining the nonparametric bootstrap with methods that address missing data","author":"Jalali","year":"2022","journal-title":"Epidemiological Reviews"},{"issue":"7","key":"10.1016\/j.jsat.2022.108835_bb0100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108835_bb0105","article-title":"The cost of providing extended-release naltrexone treatment to pre-release prisoners with opioid use disorder","author":"Jeng","year":"2021","journal-title":"Addiction Health Services Research"},{"issue":"12","key":"10.1016\/j.jsat.2022.108835_bb0110","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice- referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs (Millwood)"},{"issue":"9776","key":"10.1016\/j.jsat.2022.108835_bb0115","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jsat.2022.108835_bb0120","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.jsat.2022.108835_bb0125","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"issue":"10118","key":"10.1016\/j.jsat.2022.108835_bb0130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine- naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jsat.2022.108835_bb0135","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1001\/jama.2019.5523","article-title":"Medication-based treatment to address opioid use disorder","volume":"321","author":"Leshner","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2022.108835_bb0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2017.04.002","article-title":"Extended-release naltrexone for opioid use disorder started during or following incarceration","volume":"85","author":"Lincoln","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"34","key":"10.1016\/j.jsat.2022.108835_bb0145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.15585\/mmwr.mm6734a2","article-title":"Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016\u2013june 2017","volume":"67","author":"Mattson","year":"2018","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"3","key":"10.1016\/j.jsat.2022.108835_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The Fifth Edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108835_bb0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2016.01.021","article-title":"Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial","volume":"161","author":"Murphy","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2022.108835_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-020-00188-5","article-title":"Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): Protocol for an evaluation of two randomized effectiveness trials","volume":"15","author":"Murphy","year":"2020","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"10.1016\/j.jsat.2022.108835_bb0165","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2022.108835_bb0170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"PharmacoEconomics"},{"issue":"8","key":"10.1016\/j.jsat.2022.108835_bb0175","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2022.108835_bb0180","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences","year":"2019"},{"issue":"9","key":"10.1016\/j.jsat.2022.108835_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2022.108835_bb0190","series-title":"Cost- effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2022.108835_bb0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","article-title":"Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey","volume":"105","author":"Nunn","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.jsat.2022.108835_bb0205","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jval.2020.12.023","article-title":"Economic evaluations of pharmacologic treatment for opioid use disorder: A systematic literature review","volume":"24","author":"Onuoha","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.jsat.2022.108835_bb0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.drugalcdep.2018.04.034","article-title":"Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons","volume":"189","author":"Pizzicato","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.jsat.2022.108835_bb0215","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","article-title":"Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: Data from a randomized trial","volume":"105","author":"Polsky","year":"2010","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jsat.2022.108835_bb0220","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","article-title":"Opioid overdose mortality among former North Carolina inmates: 2000\u20132015","volume":"108","author":"Ranapurwala","year":"2018","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2022.108835_bb0225","series-title":"Medications for opioid use disorder: For healthcare and addiction professionals, policymakers, patients, and families","year":"2018"},{"issue":"14","key":"10.1016\/j.jsat.2022.108835_bb0230","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2022.108835_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2022.108835_bb0240","series-title":"Timeline follow-back: A technique for assessing self-reported alcohol consumption. (Measuring Alcohol Consumption)","author":"Sobell","year":"2007"},{"key":"10.1016\/j.jsat.2022.108835_bb0245","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"issue":"2\u20133","key":"10.1016\/j.jsat.2022.108835_bb0255","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10550887.2015.1059217","article-title":"Addiction treatment within U.S. correctional facilities: bridging the gap between current practice and evidence-based care","volume":"34","author":"Wakeman","year":"2015","journal-title":"Journal of Addictive Diseases"},{"issue":"1","key":"10.1016\/j.jsat.2022.108835_bb0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/13696998.2020.1858581","article-title":"Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder","volume":"24","author":"Wang","year":"2021","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.jsat.2022.108835_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108355","article-title":"Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison","volume":"127","author":"Woody","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2022.108835_bb0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1078345819852133","article-title":"Screening for opioid use disorder in the largest jail in Arkansas: A brief report","volume":"25","author":"Zaller","year":"2019","journal-title":"Journal of Correctional Health Care"},{"key":"10.1016\/j.jsat.2022.108835_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108292","article-title":"Cost and cost-effectiveness of interim methadone treatment and patient navigation initiated in jail","volume":"217","author":"Zarkin","year":"2020","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:53Z","timestamp":1760039813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"alternative-id":["S0740547222001179"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108835","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108835"}}